X
BPMC

Xponance’s Blueprint Medicines BPMC Stock Holding History

Xponance’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,971
Closed -$637K – 1535
2025
Q2 		$637K Sell
4,971
-50
-1% -$5.19K 0.01% 861
2025
Q1 		$444K Buy
5,021
+240
+5% +$23.4K ﹤0.01% 974
2024
Q4 		$417K Buy
4,781
+525
+12% +$48.1K ﹤0.01% 1009
2024
Q3 		$394K Buy
4,256
+82
+2% +$8.14K ﹤0.01% 1011
2024
Q2 		$450K Buy
4,174
+315
+8% +$31.5K ﹤0.01% 938
2024
Q1 		$366K Sell
3,859
-239
-6% -$20.5K ﹤0.01% 1029
2023
Q4 		$378K Buy
+4,098
New +$266K ﹤0.01% 1013
2023
Q3 		– Sell
-3,556
Closed -$225K – 1245
2023
Q2 		$225K Buy
+3,556
New +$193K ﹤0.01% 1119
2022
Q4 		– Sell
-3,364
Closed -$222K – 1236
2022
Q3 		$222K Buy
+3,364
New +$216K ﹤0.01% 1067
2022
Q1 		– Sell
-2,825
Closed -$303K – 1172
2021
Q4 		$303K Buy
2,825
+22
+0.8% +$2.3K ﹤0.01% 1037
2021
Q3 		$288K Sell
2,803
-455
-14% -$42.4K 0.01% 1049
2021
Q2 		$287K Buy
+3,258
New +$299K 0.01% 1080

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Xponance's BPMC Position: Q3 2025 in Review

Xponance sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 4,971 shares — an estimated $637K sold.

Xponance first reported a position in BPMC in Q2 2021 and held it in 12 quarters. The position peaked at $637K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Xponance reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Xponance sold 4,971 Blueprint Medicines shares in Q3 2025, an estimated $637K.
  • Xponance first reported a position in Blueprint Medicines in Q2 2021 and held it in 12 quarters.
  • Xponance's Blueprint Medicines position peaked at $637K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Xponance's 13F filing for Q3 2025, filed 12 Nov 2025.